NCT01529450View on ClinicalTrials.gov

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Basal Cell Carcinoma
Interventions
DRUG

LDE225

800-mg (4 200-mg capsules/day) capsule

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Anne Chang

OTHER